New generation of echocardiography modality for myocardial characterization:
Real-time myocardial 3D Shear Wave Elastography
Boston, September 8, 2025 – eMyosound – a French medical device company focused on assessing cardiac diseases through its groundbreaking ultrasound technology – has announced it is beginning a clinical trial in three major Boston hospitals. Led by Hanna Gaggin, MD, MPH, a cardiologist at Massachusetts General Hospital, the clinical trial will begin this month at Massachusetts General Hospital, Brigham and Women’s Hospital and Boston Medical Center. The primary objective of the study is to validate the innovative technology for quantitative assessment of myocardial stiffness on heart failure with non-reduced ejection fraction and cardiac amyloidosis patients. The study is supported by an outstanding scientific advisory board with world leaders in the field including Professors Thibaud Damy, Albert Hagege, Robert Levine, Mathew Maurer, Frederick Ruberg, and Sanjiv Shah.
eMyosound was founded in 2022 and is quickly revolutionizing the field of cardiac ultrasound imaging. Applying ultrasound elastography and real-time 3D shear wave technology to quantify cardiac tissue stiffness, eMyosound can provide unique and accurate data regarding the mechanical properties and functions of the heart. The ultrasound solution analyzes cardiac tissue properties, and provides key insights into the myocardial function of patients with heart failure, cardiac amyloidosis, and other cardiomyopathies.
“We are thrilled to see our innovative technology based on ultrasound physics applied to patients with cardiac disease, especially with heart failure,” said Professor Mickaël Tanter, eMyosound co-founder and member of the French Academy of Science. “For example, HFpEF affects up to half of heart failure patients, yet is difficult to diagnose and myocardial stiffness is an important parameter for diagnosing it. Our goal is to provide healthcare professionals with more detailed and comprehensive tools for assessing myocardial and organ stiffness, while simultaneously enhancing the patient experience.”
Key highlights of eMyosound include the following:
· Quantitative assessment of the biomechanical properties of cardiac mechanics and function.
· Fast, scalable and cost-effective technology.
· Insight into the myocardial properties of the failing heart.
“An MRI is currently an option for testing the heart, but it can be costly and does not provide the true myocardial stiffness,” said Dr. Gaggin. “New solutions for the management of cardiac amyloidosis are needed.”
Professor Emmanuel Messas, eMyosound co-founder and cardiologist explained that “Myocardial stiffness is a key parameter for cardiomyopathy evaluation. Thanks to eMyosound’s innovative technology, we can for the first time evaluate in real time and in 3D myocardial stiffness using a dedicated probe and device, eMyosound’s novel technology makes the invisible now visible, and we’re thrilled to begin our clinical trial at three world-renowned hospitals located in Boston.”
Beginning in September, the clinical trial will include 150 patients among the three hospitals.
For more information about eMyosound, visit https://emyosound.com/.
About eMyosound
Established in 2022 and founded from the Physics for Medicine Paris laboratory (INSERM, CNRS, ESPCI PSL Paris), eMyosound is a medical technology company focused on developing a groundbreaking non-invasive solution for the assessment of cardiac diseases. Utilizing advanced ultrasound elastography and real-time 3D shear wave technology, eMyosound is committed to transforming cardiac diagnostics by providing quantitative and non-invasive insights into the heart’s mechanical properties.
